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Abstract
Introduction: Tuberculosis (TB) is a global infectious disease. In low-incidence countries, paediatric TB affects mostly immigrant
children and children of immigrants. We hypothesize that these children are at risk of exposure toMycobacterium tuberculosis when
they travel to the country of origin of their parents to visit friends and relatives (VFR). In this study, we aim to estimate the incidence rate
and risk factors associated to latent tuberculosis infection (LTBI) and TB in VFR children.
Methodsand analysis: A prospective study will be carried out in collaboration with 21 primary health care centres (PCC) and 5
hospitals in Catalonia, Spain. The study participants are children under 15 years of age, either immigrant themselves or born to
immigrant parents, who travel to countries with high incidence of TB (≥ 40cases/100,000 inhabitants). A sample size of 492 children
was calculated. Participants will be recruited before traveling, either during a visit to a travel clinic or to their PCC, where a
questionnaire including sociodemographic, epidemiological and clinical data will be completed, and a tuberculin skin test (TST) will be
performed and read after 48 to 72hours; patients with a positive TST at baseline will be excluded. A visit will be scheduled eight to
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twelve-weeks after their return to perform a TST and a QuantiFERON-TB Gold Plus test. The incidence rate of LTBI will be estimated
per individual/month and person/year per country visited, and also by age-group.
Ethics and dissemination: The study protocol was approved by the Clinical Research Ethics Committee of the Hospital
Universitari Mutua Terrassa (code 02/16) and the Clinical Research Ethics Committee of the Fundació Institut Universitari per a la
Recerca a l’Atenció Primària de Salut Jordi Gol i Gurina (code P16/094). Articles will be published in indexed scientific journals.
Trial registration: Clinical-Trials.gov: NCT04236765
Abbreviations: LTBI= latent infection byM. tuberculosis, PCC= primary health care centres, QFT-Plus=QuantiFERON-TBGold
Plus, TB = Tuberculosis, TST = tuberculin skin test, VFR = visit friends and relatives.
Keywords: children, incidence, interferon-gamma release assay, latent tuberculosis, travel-related infection, tuberculin test,
tuberculosis
1. Introduction
It is estimated that one third of the world population is infected
with Mycobacterium tuberculosis and that 5% to 10% of those
infected will develop tuberculosis (TB) during their lifetime.[1]
Current global figures indicate that 10 million people develop TB
every year, of which 1.1 million are children.[2]
It is important to underscore that children have a greater risk of
developing active TB after primary infection, especially before
their fifth birthday.[3] Significantly, children infected with M
tuberculosis that do not develop the disease and that do not
receive preventive treatment will constitute a reservoir of TB in
the future.[4] Consequently, the identification and administration
of preventive treatment to children with latent tuberculosis
infection (LTBI) are critical to the global TB control and
eradication efforts.[5–7]
In countries with low TB incidence, the burden of disease is
notably higher in the immigrant than in the autochthonous
population.[8–10] Importantly, this higher incidence of tuberculo-
sis persists beyond the first years after arrival to the host
country.[11,12] In fact, most new paediatric TB cases in western
countries occur in immigrant children and autochthonous
children born to immigrant parents.[5,8,9]
In Europe, TB and hepatitis C are the main imported infections
among the immigrant population.[13] The recent increase in
international travel of immigrants to their countries of origin to
visit friends and relatives (VFR)[14–16] and subsequent exposure to
Mtuberculosis in countrieswith incidences ofTBhigher than in the
host countries could partially explain the differences in incidence
between children of immigrant families and children from the
autochthonous population.[17] It seems plausible to associate
travel-related factorswith risk of contagion, including the intensity
of transmission (proportional to the local TB incidence), the
relationship and contact with the local population, the duration of
the stay, and individual host factors.[18]
However, the risk of LTBI is difficult to estimate, firstly because
of the lack of a gold standard for the diagnosis, and secondly due
to the long incubation period before the development of the TB
disease, specially in people over 5 years of age.[18]
Due to the little evidence on the risk factors associated to LTBI
and TB in VFR children, it is crucial to elucidate the epidemiology
of TB in the immigrant population and their children to better
inform public health policies aimed at reducing the number of TB
cases.[19]
The objectives of this study are (1) to estimate the incidence
rate of LTBI and TB in paediatric VFR travellers when returning
from the countries of origin of their parents and (2) to identify
risk factors associated with LTBI and TB.
2. Methods and design
An interventional, single group assignment, multicentre study will
be carriedout fromJune2017 toDecember 2020 inCatalonia. The
incidence rate of LTBI/TB in Catalonia is 12.6cases/100,000
inhabitants and 36.3cases/100,000 inhabitants among the general
and the immigrant population, respectively.[20] BCGvaccination is
not included in the national programme of immunization.
2.1. Setting and participants
Participants of the study are children that meet the inclusion
criteria, attended at any of the 5 pre-travel health clinics or at any
of the 21 primary health centres (PCC) involved in the study.
2.1.1. Inclusion criteria (all criteria must be met).
 Children less than 15 years of age, either immigrants or
children born in Spain to immigrant parents.
 Children with at least one of the parents from a high TB
incidence country. We define “high TB incidence country” as a
country with a TB incidence rate 3 times higher than in
Catalonia, namely 40cases/100,000 inhabitants or great-
er.[6,20] Countries with official reports describing an incidence
less than the value proposed but with some regions with
≥40 cases /100,000 inhabitants will also be considered of high
incidence (Fig. 1 and Table 1).
 Children travelling and accompanying at least one of the
parents to their country of origin.
 The duration of the trip must last a minimum of 21 days.
 Informed consent must be obtained from the parents or legal
guardian.
2.1.2. Exclusion criteria.
 Children with previous TB or LTBI.
 Tourist travel staying in hotels and/or resorts with scarce
contact with the autochthonous population.
 Children with primary or secondary immunodeficiency due to
treatment with corticosteroids, transplantation, treatment with
anti-tumour necrosis factor, or chronic renal insufficiency.
 Children with congenital heart disease.
 Children with cystic fibrosis and other congenital pulmonary
diseases.
2.2. Sample size
The sample size was calculated using the GRANMO v7.2, 2012
program for the study of paired proportions, accepting an alpha
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risk of 0.05 and a beta risk of 0.2 in a two-sided test. It was
estimated that 492 subjects are necessary to obtain a statistically
significant difference considering an initial LTBI proportion of
0% and a final proportion of 2%. A drop-out rate of 20% is
anticipated.
2.3. Data collection
Baseline data collection: Eligible children will be offered to
participate in the study during a programmed visit in a pre-travel
health clinic or in a PCC. In the first visit, the parents or legal
guardians will be interviewed to complete a questionnaire
including socio-demographic, epidemiological, and clinical data.
A tuberculin skin test (TST) will be performed and read 48 to 72
hours later. Figure 2 shows the study flowchart.
The TST will be made within 30 days prior to the trip. In BCG
vaccinated children, TST will be performed and if the result is
positive, a QuantiFERON-Plus© (QFT-Plus) test will be carried
out to confirm the infection. Subsequently, if the QFT-Plus test is
positive, the child will be excluded from the study and treated for
LTBI.
Follow-up: A visit will be scheduled 8 to 12 weeks after
returning from the trip. Here, a questionnaire with epidemiologi-
cal and clinical data about the trip will be completed and a TST
and QFT-Plus test will be simultaneously performed.
Children diagnosed with LTBI or TB, either at baseline or at
follow-up, will receive treatment as per national guidelines, and
relatives will be referred for contact tracing. Similarly, the
investigators will verify the need for other preventive measures
(malaria chemoprophylaxis, helminthiasis study, other immuni-
zations, etc).
Data registration: The information collected in the question-
naires will be registered and managed in REDCap (Research
Electronic Data Capture) tools hosted at Fundació de Docència I
Recerca Mutua Terrassa. REDCap is a secure, web-based
software platform designed to support data capture for research
studies.[21,22]
2.4. Outcomes
2.4.1. Primary outcome. The primary outcome is the diagnosis
of LTBI and/or TB after travelling to a high TB incidence country
in accordance with World Health Organization (WHO) guide-
lines.[1] At the end of the study, patients will be classified as: “not
infected; LTBI/TB disease; unknown/lost to follow-up”. Table 2
shows study variables and timing of data collection.
2.4.2. Secondary outcomes.
1. Sociodemographic data: sex, age, country of birth, country of
birth of mother and father.
2. Clinical data: weight and height (before and after travel), BCG
vaccination, presence of BCG scar.
3. Epidemiological data: pre-travel visit date, travel date, post-
travel visit date, return date of the travel, trip duration, travel
country, number of people that lived in host home, travel
environment (rural / urban / mixed), smokers in host home,
contact with a person suspected of having TB.
2.5. TST and QFT-Plus test procedures
Tuberculin Skin Test (TST): TST will be performed by
intradermal injection of 2 UT of PPD RT23 (Statens Serum
Institut, Copenhagen, Denmark) and read after 48 to 72hours. A
positive test is defined as an induration greater than or equal to
10mm according to recommendations from the Agència de Salut
Publica de Catalunya[23] and WHO guidelines.[1]
QuantiFERON-TB Plus (QFT-Plus) (Cellestis, Victoria,
Australia; QIAGEN, Dusseldorf, Germany): We will draw four
ml of blood per child and interpret the QFT-Plus test according to
manufacturer’s instructions. Values ≥ 0.35 IU/ml in either TB1
Figure 1. Countries considered in the study for having regions with an incidence of tuberculosis of 40cases/100,000 inhabitants or greater.
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Table 1
















Bolivia (Plurinational State of) 108 12,000
Botswana 275 6200
Brazil 45 95,000
Brunei Darussalam 68 290
Burkina Faso 48 9500
Burundi 111 12,000
Cabo Verde 46 250
Cambodia 302 49,000
Cameroon 186 47,000
Central African Republic 540 25,000
Chad 142 22,000
China 61 866,000
China, Hong Kong SAR 67 4900
China, Macao SAR 60 380
Congo 375 20,000
Côte d’Ivoire 142 36,000
Democratic People’s Republic of Korea 513 131,000
Democratic Republic of the Congo 321 270,000
Djibouti 260 2500
Dominican Republic 45 4800
Ecuador 44 7400
El Salvador 70 4500






























































Republic of Korea 66 34,000
Republic of Moldova 86 3500
Romania 68 13,000
Russian Federation 54 79,000
Rwanda 59 7300
Sao Tome and Principe 124 260
Senegal 118 19,000
Sierra Leone 298 23,000
Singapore 47 2700
Solomon Islands 74 480
Somalia 262 39,000
South Africa 520 301,000
South Sudan 146 16,000









United Republic of Tanzania 253 142,000
Uzbekistan 70 23,000
Vanuatu 46 130
Venezuela (Bolivarian Republic of) 48 14,000
















estimated incidence rate of 40 per 100,000 population or greater.
† estimated incidence rate of less than 40 per 100,000 population. Source: World Health Organization
(WHO) Tuberculosis burden estimates. https://www.who.int/tb/publications/global_report/en/.
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and/or TB2 antigen tubes will be considered positive.[24] In the
case of QFT-Plus values ≥0.2 and<0.35 (gray zone), the test will
be repeated 4 to 8 weeks later. QFT-Plus can have a positive,
negative or indeterminate result.
If TST and QFT-Plus results are discordant, the test with a
negative result will be repeated 4 to 8 weeks later.
2.6. Statistical analysis
Qualitative variables will be described using frequency tables,
and quantitative variables will be determined usingmedian, mean
and interquartile range (IQR). We will use paired proportions for
comparisons. The incidence rate of LTBI and TBwill be estimated
per individual/month and person/year per country visited and by
Table 2
Study variables and timing of data collection.
Data collection
Characteristics Type of response Baseline Follow-up
Sociodemographic data
Sex; age Nominal; Quantitative (years) ▪
Country of birth of the child Nominal ▪
Mother’s country of origin Nominal ▪
Father’s country of origin Nominal ▪
Clinical data
Weight; height Quantitative (Kg); (cm) ▪ ▪
BCG Vaccination Nominal (Yes/No type) ▪
Presence of BCG scar Nominal (Yes/No type) ▪
Infection study
Tuberculin test date Date (yyyy-mm-dd) ▪ ▪
Tuberculin test result Quantitative (mm) ▪ ▪
QFT-Plus date Date (yyyy-mm-dd) ▪
QFT-Plus result Quantitative (UI/ml)) ▪
Final diagnosis Nominal ▪
Epidemiological data
Date of visits Date (yyyy-mm-dd) ▪ ▪
Age at visits Quantitative (years) ▪ ▪
Travel country Nominal ▪
Travel date (probablea/trueb) Date (yyyy-mm-dd) ▪a ▪ b
Return date of the travel (probablea/trueb) Date (yyyy-mm-dd) ▪a ▪ b
Time between tuberculin test and travel date (probablea/trueb) Time in days ▪a ▪ b
Trip duration Quantitative (days) ▪
Time between tuberculin test and return date Time in days ▪
Number of people that lived in host home Quantitative (number of people) ▪
Travel environment Nominal (rural, urban, mixed) ▪
Smokers in host home Nominal (Yes/No type) ▪
Contact with a person suspected of having TB Nominal (Yes/No type) ▪
BCG=Bacillus Calmette–Guérin vaccine, QFT-Plus=QuantiFERON-plus test, TB= tuberculosis.
Figure 2. Timeline of study visits and procedures.
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age group. To identify factors associatedwith presence of LTBI or
TB, the Fisher exact test or Chi-square test and the Mann-
Whitney test will be used for bivariate analyses, followed by
analysis of logistic regression calculating odds ratios and 95%
confidence intervals. A 5% type I error will be estimated. Data
will be exported from the REDCap database to PASW Statistics
25 (SPSS Inc., Chicago, IL) for statistical analyses.
2.7. Ethics
This study protocol (version 2, 01/02/2016) has been approved
by the Clinical Research Ethics Committee of the Hospital
Universitari Mutua Terrassa on 24/02/2016 (code 02/16) and by
the Clinical Research Ethics Committee of the Fundació Institut
Universitari per a la recerca a l’Atenció Primària de Salut Jordi
Gol i Gurina (IDIAPJGol) on 25/04/2016 (code P16/094), in
agreement with the Declaration of Helsinki/Tokyo. All parents
or legal guardians of the participants will receive oral and
written information about the study and Informed Consent will
be obtained. Any amendment to the study protocol will be
submitted to the ethical committees for approval.
The REDCap© database will be exclusively used by the team of
researchers. The data included in the database used for statistical
analyses will be anonymized and identified with internal codes of
the project to avoid identification by the investigative team to
guarantee confidentiality.
The results of the study will be published in scientific journals
and will be presented in national and international meetings. The
results will be communicated to participants in a meeting and via
local and national media, and will also be disseminated to the
general population.
3. Discussion
This study aims to evaluate the risk of LTBI and TB in paediatric
VFR travellers that live in Catalonia, a low incidence TB
region.[20] The study will be conducted in primary care centres,
specialized travel clinics and hospital paediatric departments of
the public health-care system. The joint role of primary care and
infectious disease specialists is crucial in the implementation of
strategies aimed at the eradication of TB in this population.[25] To
our knowledge, this is the first study to prospectively analyse
collected data from VFR children.
The few studies published with adults to date suggest that in
non-VFR travellers, the risk of infection is similar to the local
annual risk of TB infection.[26] In contrast, studies conducted
with the immigrant population suggest that a significant
percentage of TB cases are related to recent travel to the
country of origin.[27] In the case of children, a population
group with higher susceptibility to develop TB after primary
infection, a case-control study from California reported an
increased risk of LTBI in young paediatric VFR travellers and
children of families that hosted visitors from countries with high
TB incidence.[28]
Awareness of travel-associated risk of disease in VFR remains
low, which might explain the scarce use of pre-travel health-care
services by the immigrant population.[29] Moreover, the diversity
of recommendations for different regions and countries demon-
strates the limited information available on this topic.[30,31]
Knowledge about the effectiveness of LTBI screening or BCG
vaccination strategies also remains poor.[32] The implementation
of strategies for the detection and treatment of LTBI cases should
be prioritized to prevent new cases of TB in the paediatric and the
adult population.[33]
Since state-level data are those usually published in official
reports and regional incidence could vary significantly within the
same country, a limitation of the study is the unavailability of
data on regional incidence, which may hinder the assessment on
the intensity of exposure toM tuberculosis.[17] In addition, due to
the specific immigration patterns of Catalonia, some countries of
origin will be overrepresented in our sample.
The lack of gold standard for LTBI diagnosis responds to its
paucibacillary nature, the quiescent state of M tuberculosis and
the localization in the mediastinal lymph nodes.[34] However, this
is a universal limitation in all studies on this issue.
The low positive predictive value of the screening tests of LTBI
in the general population constitutes another limitation.
However, in low burden countries and among high risk groups
such as immigrants and VFR travellers, tests may be useful for
LTBI screening.[35]
Similarly, the TST and interferon-g release assays have well
described limitations, which can hinder the interpretation of
results and the calculation of incidence rates, especially in the case
of discordant results.[36,37] Again, this is a universal limitation in
all studies on this issue.
The studywill implement and evaluate a new detection strategy
and management of LTBI in VFR children in a country with a
low incidence of TB. This strategy may prove useful to design
public health policies in regions with low incidence of TB with
significant numbers of VFR travellers.
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